These data establish that GIV confers resistance to clinically used drugs for ER+ breast cancer and suggest that upregulation of GIV in cancer cells in close contact with MSCs may permit disseminated ER+ breast cancer cells to survive therapy in bone marrow. Here, CCDC88A is linked to breast cancer.